FOLH1 and prostate carcinoma: Currently in the clinic, PSMA PET is predominantly indicated in recurrent or persistent prostate cancer, as a re-staging procedure following curative-intent therapy; it can also be employed as a primary staging procedure in high-risk disease and in the setting of castrate-resistant prostate cancer, which appears localized on conventional imaging.